Merck: launches phase 3 study in lymphoma

(CercleFinance.com) - Merck announced on Thursday the start of a Phase 3 clinical trial to assess the efficacy of its antibody-drug conjugate zilovertamab vedotin in the treatment of diffuse large B-cell lymphoma.


The aim of the trial is to compare the efficacy of the product in combination with the so-called "R-CHP" protocol, which combines rituximab, cyclophosphamide, doxorubicin and prednisone, with that of the R-CHP protocol alone.

The trial, which is currently recruiting its first patients, aims to enroll a total of 1,046 participants.

Merck says that zilovertamab vedotin, which has not yet been granted any marketing authorization, had obtained 'encouraging' results in phase 2.


Copyright (c) 2025 CercleFinance.com. All rights reserved.